LINC02913: A Promising Protein for Drug Targets and Biomarkers

Target Name: LINC02913

NCBI ID: G414318

LINC02913

Other Name(s): C9orf106 | long intergenic non-protein coding RNA 2913 | bA65J3.5 | Long intergenic non-protein coding RNA 2913

LINC02913: A Promising Protein for Drug Targets and Biomarkers

LINC02913 (C9orf106) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell adhesion and has been implicated in a number of diseases, including cancer.

One of the most promising aspects of LINC02913 is its potential as a drug target. Several studies have identified potential drug-like compounds that can interact with LINC02913 and enhance its effects, such as inhibitors of the protein's tyrosine kinase activity. These compounds have the potential to be used in the treatment of various diseases, including cancer.

In addition to its potential as a drug target, LINC02913 is also a potential biomarker for a number of diseases. Its expression has been implicated in the development and progression of a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it an attractive candidate for use as a diagnostic or predictive marker in these diseases.

Overall, LINC02913 is a protein that has significant potential as a drug target and biomarker. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2913

The "LINC02913 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02913 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets